ANG Lifesciences Peer Comparison

BSE: 540694

₹32.78

₹0.63 (1.96%)

As on 02-Sep-2026IST

Market cap

₹43 Cr

Revenue (TTM)

₹84 Cr

P/E Ratio

--

P/B Ratio

0.9

Div. Yield

0 %

Edit

	ANG Lifesciences	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	43	21,168	20,635	17,919	17,176
Revenue (₹ Cr)	84	2,570	2,287	3,230	2,432
Net Profit (₹ Cr)	-13.32	735.15	678.07	666.92	169.62
Net Margin (%)	-15.83	26.88	28.10	20.60	6.90
RoE (%)	-23.81	19.16	19.73	18.75	20.76
Price to Earnings	--	28.79	31.01	27.83	101.26
Price-To-Book	0.88	4.80	5.48	4.43	19.00

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	ANG Lifesciences	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	81.03	2,569.77	2,287.33	3,229.67	2,432.06
Total Income	81.78	2,735.39	2,413.29	3,237.12	2,458.54
Total Expenditure	77.74	1,628.14	1,490.75	2,090.06	2,202.20
EBITDA	3.29	941.63	796.58	1,139.61	229.86
Depreciation	6.11	57.58	78.10	281.06	17.24
EBIT	-2.81	884.05	718.48	858.55	212.62
Interest	6.61	7.69	0.88	190.64	5.72
Other Income	0.75	165.62	125.96	7.45	26.48
Exceptional Items	0.00	-49.16	0.00	-17.24	-5.13
Profit before Tax	-8.68	992.82	843.56	658.12	228.25
Provision for Tax	-1.32	257.67	165.49	-8.80	58.63
Profit after Tax	-7.36	735.15	678.07	666.92	169.62

Liabilities (₹ Cr)

	ANG Lifesciences	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	62.22	4,202.90	3,586.42	3,902.67	872.79
Minority Interest	0.00	0.00	-12.71	-21.81	0.00
Non-Current Liabilities	3.12	91.50	28.74	1,392.75	134.50
Current Liabilities	124.58	627.48	385.94	2,077.10	981.81
Total Liabilities	--	4,911.11	3,207.85	6,862.28	1,879.19

Assets (₹ Cr)

	ANG Lifesciences	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	50.64	770.28	1,291.22	5,617.77	42.47
Current Assets	132.97	3,803.22	2,585.66	1,539.85	1,739.93
Total Assets	--	4,911.11	3,207.85	6,862.28	1,879.19
Total Debt*	--	2.50	0.55	2,421.66	0.00
Net Current Assets	8.39	3,175.74	2,199.72	-537.25	758.12
Contingent Liabilities	--	363.79	0.64	64.29	98.41

Cashflow (₹ Cr)

	ANG Lifesciences	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	--	659.75	432.37	1,065.01	65.36
Cash Flow from Investing Activities	--	-71.34	-334.73	-79.97	30.80
Cash from Financing Activities	--	-205.34	-38.32	-881.32	-65.59
Net Cash Inflow / Outflow	--	383.07	59.32	103.72	30.57

Ratios

Profitability Ratios

	ANG Lifesciences	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	--	26.21	26.22	13.59	21.29
ROE (%)	-11.55	19.16	19.73	18.75	20.76
ROA (%)	-3.69	14.95	18.69	9.26	9.67
EBIT Margin (%)	-3.47	34.40	31.41	26.58	8.74
Net Margin (%)	-9.00	26.88	28.10	20.60	6.90
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	ANG Lifesciences	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	-17.54	10.69	15.01	9.59	31.10
EBIT Growth (%)	33.60	24.14	18.45	16.84	-12.99
Net Profit Growth (%)	12.04	-9.09	19.61	62.68	-7.49
EPS Growth (%)	12.04	14.40	17.73	67.41	-18.33
Book Value Growth (%)	--	17.30	23.77	10.19	7.70

Valuation Ratios

	ANG Lifesciences	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	-5.82	27.44	31.01	27.16	98.97
Price / Book Value	0.73	4.80	5.48	4.43	19.00
Dividend Yield (%)	0.00	1.62	0.15	0.54	0.52
EV/EBITDA	36.32	19.18	24.77	17.65	72.77
Market Cap (₹ Cr)	--	18,318.10	15,219.80	19,292.77	21,515.93

Solvency Ratios

	ANG Lifesciences	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.01	0.00	0.00	0.24	0.00
Short term debt to equity ratio	--	0.00	0.00	0.14	--
Current Ratio	1.07	6.06	6.70	0.74	1.77
Quick Ratio	0.80	5.31	5.59	0.53	0.73
Interest Coverage	-0.31	130.11	959.59	4.45	40.90

Operating Efficiency Ratios

	ANG Lifesciences	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	80.65	7.07	36.10	21.07	8.79
Asset Turnover	0.41	0.52	0.63	0.45	1.39
Receivable days	--	29.10	110.70	54.07	35.81
Inventory Days	--	69.53	65.86	32.16	82.25
Payable days	--	76.77	105.88	140.91	124.39
Cash Conversion Cycle	--	21.86	70.68	-54.68	-6.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.